325 related articles for article (PubMed ID: 30396842)
21. Assessment of Outcome of Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma by the Combination of RECIST and Tumor Markers.
Hatooka M; Kawaoka T; Aikata H; Honda F; Nakamura Y; Nakano N; Morio K; Fukuhara T; Kobayashi T; Nagaoki Y; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Chayama K
Hiroshima J Med Sci; 2016 Sep; 65(2):25-33. PubMed ID: 29989682
[TBL] [Abstract][Full Text] [Related]
22. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
23. Cone-Beam CT-Guided Chemoembolization in Patients with Complete Response after Previous Chemoembolization but Subsequent Elevated α-Fetoprotein without Overt Hepatocellular Carcinoma.
Wattanasatesiri T; Kim HC; Choi JW; Lee JH; Joo I; Hur S; Lee M; Jae HJ; Chung JW
J Vasc Interv Radiol; 2019 Aug; 30(8):1273-1280. PubMed ID: 31235410
[TBL] [Abstract][Full Text] [Related]
24. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
25. The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.
Liu L; Zhao Y; Jia J; Chen H; Bai W; Yang M; Yin Z; He C; Zhang L; Guo W; Niu J; Yuan J; Cai H; Xia J; Fan D; Han G
Sci Rep; 2016 Feb; 6():19851. PubMed ID: 26831408
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
Miyaki D; Kawaoka T; Aikata H; Kan H; Fujino H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Hyogo H; Kawakami Y; Yoshimatsu R; Yamagami T; Awai K; Chayama K
J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Park WH; Shim JH; Han SB; Won HJ; Shin YM; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2012 Jul; 23(7):927-36. PubMed ID: 22633621
[TBL] [Abstract][Full Text] [Related]
29. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
[TBL] [Abstract][Full Text] [Related]
30. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
Memon K; Kulik L; Lewandowski RJ; Wang E; Ryu RK; Riaz A; Nikolaidis P; Miller FH; Yaghmai V; Baker T; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R
J Hepatol; 2012 May; 56(5):1112-1120. PubMed ID: 22245905
[TBL] [Abstract][Full Text] [Related]
31. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
[TBL] [Abstract][Full Text] [Related]
33. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
[TBL] [Abstract][Full Text] [Related]
34. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort.
Sandow T; Pavlus J; Field D; Lacayo E; Cohen E; Lynskey G; Caridi T; Buckley D; Cardella J; Kallakury B; Spies J; Kim AY
J Vasc Interv Radiol; 2019 Jul; 30(7):995-1003. PubMed ID: 31109853
[TBL] [Abstract][Full Text] [Related]
35. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
36. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy.
Paul SB; Sahu P; Sreenivas V; Nadda N; Gamanagatti SR; Nayak B; Shalimar S; Acharya SK
Scand J Gastroenterol; 2019 Sep; 54(9):1132-1137. PubMed ID: 31483691
[No Abstract] [Full Text] [Related]
38. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
Kim BK; Kim KA; Park JY; Ahn SH; Chon CY; Han KH; Kim SU; Kim MJ
Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
[TBL] [Abstract][Full Text] [Related]
39. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
[TBL] [Abstract][Full Text] [Related]
40. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]